Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
复制标题
DOI：
10.1002/cncr.28144
复制
发表时间：
2013-09-01
期刊：
影响因子：
6.2
通讯作者：
Yu, David S.
中科院分区：
文献类型：
--
作者：
Colbert, Lauren E.;Fisher, Sarah B.;Hardy, Claire W.;Hall, William A.;Saka, Burcu;Shelton, Joseph W.;Petrova, Aleksandra V.;Warren, Matthew D.;Pantazides, Brooke G.;Gandhi, Khanjan;Kowalski, Jeanne;Kooby, David A.;El-Rayes, Bassel F.;Staley, Charles A., III;Adsay, N. Volkan;Curran, Walter J., Jr.;Landry, Jerome C.;Maithel, Shishir K.;Yu, David S.
混合谱系激酶结构域样蛋白（MLKL）是介导程序性坏死的坏死体成分，可能是癌细胞死亡的重要决定因素。本研究的目的是评估MLKL表达对胰腺癌（PAC）患者的预后价值。从2000年1月至2008年10月期间接受胰腺炎切除术的PAC患者的前瞻性数据库中收集了80例患者的组织。进行免疫组织化学分析，并使用已建立的评分系统进行评分。生成所有患者和接受辅助化疗患者的无复发生存期（RFS）和总生存期（OS）的Kaplan-Meier生存曲线。采用纳入临床相关协变量的单变量和多变量考克斯回归分析，将MLKL评分与RFS和OS相关。患者的中位年龄为63岁，53%为男性。MLKL低表达与OS下降相关（6个月vs 17个月; P=.006）。在接受辅助化疗的59例患者中，MLKL低表达与RFS降低（5个月vs 15个月; P= 0.006）和OS降低（6个月vs 19个月; P<0.0001）相关。在多变量分析中，MLKL低表达与所有患者（风险比，4.6 [95%置信区间，1.6-13.8]; P= 0.006）和接受辅助化疗的患者（风险比，8.1 [95%置信区间，2.2-29.2]; P= 0.002）的OS差相关。MLKL的低表达与PAC切除患者的OS降低以及接受辅助化疗的PAC切除患者亚组的RFS和OS降低相关。在PAC患者中使用这种生物标志物可能提供重要的预后信息。
Mixed lineage kinase domain-like protein (MLKL) is a necrosome component mediating programmed necrosis that may be an important determinant of cancer cell death. The goal of the current study was to evaluate the prognostic value of MLKL expression in patients with pancreatic adenocarcinoma (PAC). Tissue from 80 patients was collected from a prospectively maintained database of patients with PAC who underwent pancreaticoduodenectomy between January 2000 and October 2008. Immunohistochemistry analysis was performed and scored using an established scoring system. Kaplan-Meier survival curves were generated for recurrence-free survival (RFS) and overall survival (OS) for all patients and for patients receiving adjuvant chemotherapy. MLKL scores were correlated with RFS and OS using univariate and multivariate Cox regression analyses incorporating clinically relevant covariates. The median age of the patients was 63 years and 53% were men. Low MLKL expression was associated with decreased OS (6 months vs 17 months; P=.006). In the subset of 59 patients who received adjuvant chemotherapy, low MLKL expression was associated with decreased RFS (5 months vs 15 months; P=.006) and decreased OS (6 months vs 19 months; P<.0001). On multivariate analysis, low MLKL expression was associated with poor OS in all patients (hazards ratio, 4.6 [95% confidence interval, 1.6-13.8]; P=.006) and in patients receiving adjuvant chemotherapy (hazards ratio, 8.1 [95% confidence interval, 2.2-29.2]; P=.002). Low expression of MLKL is associated with decreased OS in patients with resected PAC and decreased RFS and OS in the subset of patients with resected PAC who receive adjuvant chemotherapy. The use of this biomarker in patients with PAC may provide important prognostic information.
登录
查看更多内容
影响因子：
2.9
作者：
Basturk O;Singh R;Kaygusuz E;Balci S;Dursun N;Culhaci N;Adsay NV
通讯作者：
Adsay NV
影响因子：
3.7
作者：
Maupin KA;Sinha A;Eugster E;Miller J;Ross J;Paulino V;Keshamouni VG;Tran N;Berens M;Webb C;Haab BB
通讯作者：
Haab BB
DOI：
10.1126/science.1203430
发表时间：
2011-06-10
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Cotta-Ramusino C;McDonald ER 3rd;Hurov K;Sowa ME;Harper JW;Elledge SJ
通讯作者：
Elledge SJ
核糖核苷酸还原酶小亚基M2B预测结直肠癌的生存更好。
影响因子：
11.2
作者：
Liu X;Lai L;Wang X;Xue L;Leora S;Wu J;Hu S;Zhang K;Kuo ML;Zhou L;Zhang H;Wang Y;Wang Y;Zhou B;Nelson RA;Zheng S;Zhang S;Chu P;Yen Y
通讯作者：
Yen Y
影响因子：
16
作者：
Paulsen, Renee D.;Soni, Deena V.;Wollman, Roy;Hahn, Angela T.;Yee, Muh-Ching;Guan, Anna;Hesley, Jayne A.;Miller, Steven C.;Cromwell, Evan F.;Solow-Cordero, David E.;Meyer, Tobias;Cimprich, Karlene A.
通讯作者：
Cimprich, Karlene A.